X4 Pharmaceuticals, Inc. (XFOR) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "XFOR"
      ],
      "issuer_cik": "0001501697",
      "owner_cik": "0001339498",
      "accession_number": "0001339498-26-000005",
      "form_type": "4",
      "filing_date": "2026-10-19",
      "period_of_report": "2026-10-16",
      "issuer_name": "X4 Pharmaceuticals, Inc",
      "issuer_trading_symbol": "XFOR",
      "owner_name": "Craig Adam R",
      "is_director": true,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "Executive Chairman",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": false,
      "transaction_date": "2026-10-16",
      "transaction_code": "P",
      "equity_swap_involved": false,
      "transaction_shares": 4600,
      "transaction_price_per_share": 2.5834,
      "transaction_acquired_disposed": "A",
      "shares_owned_following_transaction": 333251,
      "transaction_value": 11883.640000000001,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "Of the shares of common stock reported, 193,254 shares represent restricted stock units."
        },
        {
          "id": "F2",
          "description": "The Reporting Person has agreed to disgorge to the Issuer all profits deemed to be realized from this transaction pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended."
        }
      ]
    },
    {
      "tickers": [
        "XFOR"
      ],
      "issuer_cik": "0001501697",
      "owner_cik": "0001276750",
      "accession_number": "0001501697-26-000078",
      "form_type": "4",
      "filing_date": "2026-10-05",
      "period_of_report": "2026-10-01",
      "issuer_name": "X4 Pharmaceuticals, Inc",
      "issuer_trading_symbol": "XFOR",
      "owner_name": "KIRSKE DAVID",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "Chief Financial Officer",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": false,
      "transaction_date": "2026-10-01",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 11767,
      "transaction_price_per_share": 2.8604,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 155983,
      "transaction_value": 33658.326799999995,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."
        },
        {
          "id": "F2",
          "description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.82 to $2.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
        },
        {
          "id": "F3",
          "description": "Of the shares of common stock reported, 64,418 shares represent restricted stock units."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.